| Rachel Marie Schroeder, CNP | |
|
1000 1st Dr Nw, Austin, MN 55912-2941 | |
| (507) 433-7351 | |
| Not Available |
| Full Name | Rachel Marie Schroeder |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 1000 1st Dr Nw, Austin, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063131688 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 9451 (Minnesota) | Secondary |
| 363L00000X | Nurse Practitioner | 9451 (Minnesota) | Primary |
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164463659 PECOS PAC ID: 1951213487 Enrollment ID: O20031104000095 |
News Archive
The probability of blindness due to the serious eye disease glaucoma has decreased by nearly half since 1980, according to a study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers speculate that advances in diagnosis and therapy are likely causes for the decrease, but caution that a significant proportion of patients still progress to blindness.
St. Jude Children's Research Hospital investigators discuss results of research into managing iron overload associated with stroke prevention in young sickle cell patients and the search for genetic predictors of stroke risk.
Agilent Technologies Inc. and Stemina Biomarker Discovery, Inc. today announced efforts to accelerate Stemina's metobolomic research. Stemina uses metabolomic analysis of stem cells for the discovery of biomarkers for use in drug screening and drug development.
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.
› Verified 9 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891701637 PECOS PAC ID: 4385556703 Enrollment ID: O20031104000408 |
News Archive
The probability of blindness due to the serious eye disease glaucoma has decreased by nearly half since 1980, according to a study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers speculate that advances in diagnosis and therapy are likely causes for the decrease, but caution that a significant proportion of patients still progress to blindness.
St. Jude Children's Research Hospital investigators discuss results of research into managing iron overload associated with stroke prevention in young sickle cell patients and the search for genetic predictors of stroke risk.
Agilent Technologies Inc. and Stemina Biomarker Discovery, Inc. today announced efforts to accelerate Stemina's metobolomic research. Stemina uses metabolomic analysis of stem cells for the discovery of biomarkers for use in drug screening and drug development.
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.
› Verified 9 days ago
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1538113022 PECOS PAC ID: 1951213487 Enrollment ID: O20070711000490 |
News Archive
The probability of blindness due to the serious eye disease glaucoma has decreased by nearly half since 1980, according to a study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers speculate that advances in diagnosis and therapy are likely causes for the decrease, but caution that a significant proportion of patients still progress to blindness.
St. Jude Children's Research Hospital investigators discuss results of research into managing iron overload associated with stroke prevention in young sickle cell patients and the search for genetic predictors of stroke risk.
Agilent Technologies Inc. and Stemina Biomarker Discovery, Inc. today announced efforts to accelerate Stemina's metobolomic research. Stemina uses metabolomic analysis of stem cells for the discovery of biomarkers for use in drug screening and drug development.
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.
› Verified 9 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1063435410 PECOS PAC ID: 4385556703 Enrollment ID: O20171011003946 |
News Archive
The probability of blindness due to the serious eye disease glaucoma has decreased by nearly half since 1980, according to a study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers speculate that advances in diagnosis and therapy are likely causes for the decrease, but caution that a significant proportion of patients still progress to blindness.
St. Jude Children's Research Hospital investigators discuss results of research into managing iron overload associated with stroke prevention in young sickle cell patients and the search for genetic predictors of stroke risk.
Agilent Technologies Inc. and Stemina Biomarker Discovery, Inc. today announced efforts to accelerate Stemina's metobolomic research. Stemina uses metabolomic analysis of stem cells for the discovery of biomarkers for use in drug screening and drug development.
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rachel Marie Schroeder, CNP 1000 1st Dr Nw, Austin, MN 55912-2941 Ph: (507) 433-5735 | Rachel Marie Schroeder, CNP 1000 1st Dr Nw, Austin, MN 55912-2941 Ph: (507) 433-7351 |
News Archive
The probability of blindness due to the serious eye disease glaucoma has decreased by nearly half since 1980, according to a study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers speculate that advances in diagnosis and therapy are likely causes for the decrease, but caution that a significant proportion of patients still progress to blindness.
St. Jude Children's Research Hospital investigators discuss results of research into managing iron overload associated with stroke prevention in young sickle cell patients and the search for genetic predictors of stroke risk.
Agilent Technologies Inc. and Stemina Biomarker Discovery, Inc. today announced efforts to accelerate Stemina's metobolomic research. Stemina uses metabolomic analysis of stem cells for the discovery of biomarkers for use in drug screening and drug development.
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use.
› Verified 9 days ago
Kim Wangen, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-433-7351 | |
Alice Marie Kaasa, CNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-434-1092 Fax: 507-434-1477 | |
Britt Kiersten Schultz, DNP, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-433-8758 | |
Mrs. Dawn Marie Bos, PHD, ARNP, FNP,PMHNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 101 21st St Se Ste 1, Austin, MN 55912 Phone: 507-437-6389 Fax: 507-337-2926 | |
Sarah Sistek, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-433-7351 | |
Joanne Marie Mcgaffey, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-433-7351 Fax: 507-434-1927 |